Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults

• Biological: 13-valent pneumococcal conjugate vaccine
  
  Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM), followed by a single 0.5 mL vaccine 13vPnC placebo, 1 month later.
• Biological: 13vPnC + TIV
  
  Single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, administered IM, followed by a single 0.5 mL 13vPnC vaccine, 1 month later.

• Experimental: 13vPnC+TIV Followed by Placebo 1 month later
  
  Intervention: Biological: 13-valent pneumococcal conjugate vaccine
• Active Comparator: Placebo+TIV Followed by 13vPnC 1 month later
  
  Intervention: Biological: 13vPnC + TIV

Inclusion Criteria:

• Generally healthy male or female adults 65 years of age or older.
• Available for the duration of the trial - approximately 2 months.
• No previous vaccination with any pneumococcal vaccine.
• No history of severe adverse reaction associated with a vaccine.
• No allergy to egg proteins (eggs or egg products) and chicken proteins.